NuVasive IPO: Minimally Invasive Spine Firm Offers Up To $92 Mil. In Stock
This article was originally published in The Gray Sheet
Executive Summary
NuVasive plans to use proceeds from its initial public offering to develop injectable disc nucleus replacement materials and total lumbar disc products
You may also be interested in...
NuVasive Prepares Cervical Disc IDE Filing; Fusion Plate To Launch In July
NuVasive intends to file an IDE application for a minimally-invasive cervical total artificial disc replacement within the next two weeks
NuVasive Prepares Cervical Disc IDE Filing; Fusion Plate To Launch In July
NuVasive intends to file an IDE application for a minimally-invasive cervical total artificial disc replacement within the next two weeks
NuVasive Facility Expansion Triples Capacity; Stock Up 24% In January
Spinal surgery system maker NuVasive's recently expanded production, training and warehousing capacity is spurring investor optimism that drove a 24.3% stock price increase in January to $12.7